TY  - JOUR
A1  - Douer, Dan
A1  - Gökbuget, Nicola
A1  - Stock, Wendy
A1  - Boissel, Nicolas
T1  - Optimizing use of L-asparaginase–based treatment of adults with acute lymphoblastic leukemia
T2  - Blood reviews
N2  - Acute lymphoblastic leukemia (ALL) is a malignancy of lymphoid progenitor cells occurring at an annual incidence rate of approximately 1.1 to 2.1 per 100,000 person-years globally. Approximately 40% of annual ALL cases occur in adults, yet estimated 5-year overall survival rates are about 40% to 50% in adults (and vary broadly by age) compared with 90% in children. Although the addition and/or intensification of asparaginase as a key treatment strategy for pediatric ALL is well recognized, further research is needed to clarify the benefit/risk ratio in adult patients with ALL. This review emphasizes the importance of efficient management of adverse events to increase asparaginase efficacy and explores novel strategies for optimizing asparaginase treatment, including new formulations of asparaginase, pharmacokinetic-based dosing, and pharmacogenetic profiling. Upcoming results of adult ALL trials should further clarify the role of asparaginase, building on the results of the large NOPHO 2008, CALGB 10403, GRAALL-2005, GMALL 07/2003, and UKALL14 trials.
KW  - Acute lymphoblastic leukemia
KW  - Adults
KW  - Asparaginase
KW  - Efficacy
KW  - Safety
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63107
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-631072
SN  - 0268-960X
N1  - Medical writing and editorial assistance were provided by Larry Deblinger, of The Curry Rockefeller Group (CRG), and Nancy Tang, PharmD, of SciFluent Communications, Inc./Cello Health Communications, and were financially supported by Jazz Pharmaceuticals
VL  - 53
SP  - 1
EP  - 12
PB  - Elsevier
CY  - Amsterdam
ER  -